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Abstract: Frequently used experimental models
of sepsis include cecal ligation and puncture, as-
cending colon stent peritonitis, and the i.p. or i.v.
injection of bacteria or bacterial products (such as
LPS). Many of these models mimic the pathophys-
iology of human sepsis. However, identification of
mediators in animals, the blockade of which has
been protective, has not translated into clinical
efficacy in septic humans. We describe the short-
comings of the animal models and reasons why
effective therapy for human sepsis cannot be de-
rived readily from promising findings in animal
sepsis. J. Leukoc. Biol. 81: 137–143; 2007.
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INTRODUCTION
Sepsis with its complications is still a major challenge in
contemporary medicine. Approximately 700,000 patients are
affected annually at huge costs for the healthcare system.
Depending on the standards of medical care, the worldwide
mortality rates in septic humans range from 30% to 70% (with
an aggregate mortality rate of 50%) [1, 2]. Despite more than
20 years of extensive research and development of numerous
therapeutic approaches used in clinical settings, the incidence
of sepsis and the number of sepsis-related deaths are rising [2].
For a long a time, it was believed that sepsis was caused by an
overwhelming immune response of the patient to invading
microorganisms, but in only 50% of the patients showing
symptoms of sepsis, bacteremia can be detected by standard
culture methods [3]. This was taken into account when the
term, systemic inflammatory response syndrome (SIRS), was
established in 1992 (see below). Thus, SIRS describes a hy-
perinflammatory state of the immune/inflammatory systems
represented by elevated levels of proinflammatory mediators
with development of multi-organ dysfunction syndrome and
multi-organ failure (MOF) [4]. A tight regulation of the im-
mune/inflammatory system is crucial for maintaining the bal-
ance between protective and tissue-damaging responses. SIRS
and sepsis are characterized by a loss of control over inflam-
matory responses, which can be provoked by a variety of
causative insults.
Several different animal models of sepsis have been devel-
oped, in most of which a local intra-abdominal infection is
generated to initiate systemic inflammation. Common experi-
mental models used in sepsis research currently pursue two
different strategies: a septic focus originating from injection or
release of feces into the peritoneal cavity or injection of bac-
teria or microbial components (e.g., LPS) into the abdominal
cavity or bloodstream. These approaches attempt to mimic
pathophysiological changes typically seen in septic patients,
ranging from bacteremia to SIRS to septic shock to multi-organ
dysfunction and subsequently, death. Numerous therapeutic
attempts have targeted proinflammatory mediators and have
had promising effects when used in animal models of sepsis,
but virtually all have failed to demonstrate clinical efficacy in
human clinical trials [5, 6]. Although typical symptoms such as
hyperthermia (progressing to hypothermia), tachycardia, and
tachypnea can be observed in septic animals, other parameters
such as levels of pro- and anti-inflammatory cytokines differ
between animals and humans with sepsis, providing a possible
explanation as to why human clinical trials based on effective
treatment strategies in animals have failed. As a result, the
initial euphoria and optimism to find a potent therapeutic
strategy for septic patients were dampened, and pharmaceuti-
cal companies often consider sepsis research to be a “grave-
yard” rather than a promising investment with payoff.
In this review, the more frequently used models of experi-
mental sepsis are discussed with their advantages and disad-
vantages and limitations. We try to bridge the gap between
animal and human sepsis to address the question as to why
insights from animal studies cannot be transferred categori-
cally from the laboratory to the clinical setting.
HUMAN SEPSIS
SIRS is defined by the combination of typical clinical symp-
toms in the presence (sepsis) or absence (SIRS) of microbial
(bacterial, fungal, or parasitic) infection: hypo/hyperthermia
(36°C or 38°C), tachycardia (90 beats per minute),
tachypnea (20 breaths per minute or PaCO232 mmHg), and
leukocytosis/leukopenia {white blood cell count 12,000/mm3
or 4000/mm3 or presence of 10% immature (band) forms;
Table 1; ref. [4]}. The most frequent sources of infection are
lung, abdomen, and urinary tract, but in only 40–60% of
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patients with sepsis does bacteremia occur. Originally, the
leading cause of septic shock was considered to be an infection
with gram-negative bacteria, but gram-positive infections in
sepsis are currently as frequent or more so than gram-negative
infections, followed by fungi and parasites as causative agents
of sepsis [7]. It should be noted that the frequency of fungal
sepsis has been on the rise [8].
At particular risk to develop SIRS or sepsis are elderly and
immunocompromised patients. The average age of patients
with sepsis or septic shock ranges from 60 to 65 years [2]. As
would be expected, the risk of mortality rises with increasing
age [1, 9]. In addition, a variety of underlying diseases as well
as presence of organ dysfunction and the individual’s genetic
predisposition may increase the risk of SIRS and sepsis [10].
The initial insult or infection can lead to an overwhelming
reaction of the innate immune system with activation of proin-
flammatory cascades (e.g., the complement system) and ap-
pearance of various mediators (TNF-, IL-1, IL-6, C5a, and
many more), resulting in SIRS and progressive MOF [11, 12].
At some point in sepsis, anti-inflammatory factors [such as
IL-4, IL-10, IL-1 receptor antagonist (IL-1RA), and others] are
released, perhaps representing a compensatory, anti-inflamma-
tory response, although this is debatable. Too much proinflam-
matory mediator release may trigger an uncontrolled, inflam-
matory response, resulting in consumptive depletion of the
clotting system, and excessive release of anti-inflammatory
mediators may contribute to immunosuppression or anergy,
which occurs in humans with sepsis. In this regard, there may
be iatrogenic reasons for compromised immune system func-
tion in septic patients. Inotropic agents, morphine, and allo-
genic blood transfusions are known to induce immunosuppres-
sion [13–16]. The coincidence of the imbalance of the immune
and inflammatory responses during SIRS and sepsis is still





The systemic administration of endotoxin as a model of sepsis
underlies the notion that it is the host response that causes the
clinical features of sepsis and not the intact pathogen per se.
Endotoxin is part of the outer membrane of the cell envelope of
gram-negative bacteria. The term endotoxin is often used ex-
changeably with LPS, as LPS represents the main biologically
active component of endotoxin. The i.v. infusion of LPS as well
as its instillation into the abdominal cavity causes sepsis-like
symptoms, accompanied by similarities to pathophysiological
responses in patients with sepsis, such as hematological alter-
ations [17]. Furthermore, LPS infusion induces an increase of
proinflammatory cytokines in serum [18, 19], another parallel
to septic patients, whose elevated cytokine levels correlate with
severity of the disease [20]. TNF- and IL-1 have emerged to
play a crucial role in the development of in vivo responses to
LPS and have become targets of therapeutic interventions in
septic humans [21]. The injection of recombinant TNF- or
IL-1 can induce many of the features caused by LPS and by
sepsis itself [22, 23]. Based on promising results of TNF-
blockade in LPS animal studies, several clinical trials were
performed using TNF- antibodies or soluble receptors
(TNF-SR p55, p75). In trials using the SR p55, there was no
improvement of survival [24]. A study with p75 even showed a
dose-dependent increase of mortality in septic patients [24].
Overall, these trials failed to improve survival, although a trial
meta-analysis of a cohort of the more seriously ill septic
humans suggested a beneficial effect of TNF- blockade [25].
The need to identify a subset of septic humans who would
benefit from TNF- blockade substantially limits this type of
intervention in septic humans. Similarly, the blockade of IL-1
by the so-called IL-1RA did not significantly reduce sepsis-
related mortality in large clinical trials [26]. Only patients with
the highest risk of death seemed to benefit from use of IL-1RA
[27]. Finally, it turns out that the LPS experimental model and
sepsis in humans differ in several key points, especially in the
profile of cytokine release. Cytokine levels (TNF-, IL-6, CXC
chemokines) peaked much later and occurred at much lower
levels in human patients with sepsis as well as in the model of
cecal ligation and puncture (CLP; described in detail below)
when compared with effects of LPS infusion [12, 17]. Such
findings suggested that the LPS model may not accurately
reflect sepsis in the CLP model or in septic humans. Another
confounding factor related to the linkage of TNF- with sepsis
is the finding that in CLP mice, the interception of TNF- with
antibody actually made survival worse [28–30]. The hypothesis
TABLE 1. Human Sepsis Criteria
SIRS:
hyperthermia or hypothermia core body temperature  38°C or 36°C
tachycardia 90 beats/min
tachypnea 20 breaths/min or PaCO2  32 mmHg or respiratory support




sepsis  organ failure (lactacidosis, kidney failure, ARDS,a liver failure, thrombocytopenia)
septic shock:
severe sepsis  hypotension
a ARDS, Acute respiratory distress syndrome.
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that circulating endotoxin (LPS) causes shock in sepsis is
contestable [31], as when endotoxin is detected in the blood of
patients with sepsis, the levels are low [32]. It is not surprising
that blocking of endotoxin (with antibody) in septic humans as
well as other therapeutic interventions failed to show beneficial
effects [33]. Endotoxemia has been used in baboons [34] and in
human volunteers [19, 35] to define the temporal patterns and
diversity of mediators appearing in the blood compartment.
Infusion of live, gram-negative bacteria (Escherichia coli) has
been used in nonhuman primates [34]. In these models, block-
ade of TNF- has generally been protective, but the real
question here is whether such findings can be applied to septic
humans. As a result of these many observations, the LPS model
may not represent a valid model to simulate sepsis, although it
can be used to determine the pathophysiology of endotoxemia
(Table 2).
Fecal pellet model and bacterial inoculum model
The model of fecal pellet peritonitis mimics sepsis induced by
i.p. administration of feces [36]. A pellet most commonly
within a fibrin clot is used [37, 38]. Without additives, feces
instillation leads to rapid death or recovery of the animals [39].
In many respects, the fecal pellet model, with the mixed
aerobic and anaerobic flora, resembles the CLP and the colon
ascendens stent peritonitis (CASP) models (below). The fecal
pellet model has been widely replaced by other models, such
as the bacterial inoculum model.
The bacterial inoculum model features a known number of
E. coli CFU, which are infused i.p. [40]. Usually, “adjuvants”
may be added [40], but the procedure can also be performed
without such additives [41, 42]. Injection of pure cultures of
bacteria without a carrier is considered to represent another
model of endotoxin shock rather than of peritonitis [43]. Nu-
merous variants of i.p. bacterial delivery exist, such as using
different species of bacteria (e.g., Bacteroides fragilis) or a
combination (E. coli plus B. fragilis) [44]. The mortality rate
depends on the species of animals used and the number of
bacteria administered, so that this model becomes more con-
trollable and reproducible than the fecal pellet deposition. The
fecal pellet and bacterial inoculum models mimic abscess
formation following peritonitis rather than abdominal sepsis,
especially when B. fragilis is involved [45]. This could be the
reason why treatment with antibiotics and fluid resuscitation
reduces the mortality rate to 20%; in this model, the abscess is
often walled off [46].
CASP model
A CASP model has been used to induce sepsis in mice. The
idea behind this model is that intestinal leakage (e.g., after
major abdominal surgery) leads to bacterial invasion of the
peritoneal cavity followed by organ failure, septic shock, and
death. A stent is inserted into the ascending colon, generating
a septic focus [47]. With a maximum mortality of 100% within
the first 48 h, the use of stents of different sizes can modify
mortality rates. The CASP model has been shown to result in
organ dysfunction similar to that seen in septic patients. Acute
lung injury, renal failure, and bone marrow cell dysfunction
have been reported following CASP [48–50]. Proinflammatory
mediators such as IL-1 and IFN- are thought to play an
important role in this model of sepsis as well [47, 51]. Survival
in the CASP model seems to be TNF--independent as op-
posed to the CLP model (see below) [47]. Although pathophys-
iological changes after CASP appear to be similar to those in
human sepsis, the nature of the model limits its use. Stenting
the colon ascendens creates a constant leakage of bowel con-
tent, mimicking the situation of an insufficient anastomosis
following bowel surgery, which is often followed by sepsis.
CLP model
Similar to CASP, an abdominal septic focus leads to a polymi-
crobial infection of the peritoneum in the model of CLP,
eventually resulting in bacteremia, SIRS, sepsis, septic shock,
and usually death. This model features ligation immediately
below the ileocecal valve followed by through-and-through
needle puncture of the cecum. Subsequently, animals develop
typical symptoms of sepsis or septic shock and a high mortality
rate [28, 49]. Since the first description of the CLP procedure,
it has been used extensively as a model for experimental sepsis
[52]. Besides analysis of survival, the complex pattern of
cytokine expression has been investigated extensively. The
main proinflammatory cytokines, IL-6 and TNF-, have been
shown to increase following CLP. Further, it has been reported
that high levels of IL-6 strongly correlate with survival after
CLP, a phenomenon that also occurs in human sepsis [53–55].
We have investigated the role of the anaphylatoxin C5a and its
receptor C5aR during sepsis. Using the CLP model, we have
found that blocking C5a or C5aR by administration of antibody
significantly improves survival and prevents the development
of organ dysfunction [56, 57]. Similarly, blockade of IL-6
results in increased survival of septic mice following CLP [58].
In contrast, if TNF- were inhibited by administration of
TNF- antibodies or using p55 (TNF-R I)-deficient mice, the
mortality increased [57–60]. As described above, levels of
TNF- peak earlier and are much higher in the LPS model
than in the CLP model.
Despite its clinical relevance and widespread use in sepsis
research, a concern of the CLP model is consistency. The
outcome after CLP is strongly associated with several factors
TABLE 2. Comparison of LPS Infusion and CLP Model in Rodents
LPS infusion Cecal ligation and puncture
clinical symptoms (rapid hypothermia) develop within a few hours clinical symptoms develop within 12–24 h
leukopenia followed by leukocytosis leukocytosis or leukopenia
early, high transient levels of proinflammatory cytokines
(IL-1, TNF-, IL-6)
late, moderately high levels of proinflammatory cytokines
(IL-1, TNF-, IL-6, C5a)
protective effects of anti-TNF- anti-LPS or anti-TNF- without protection
serum LPS levels very low to nondetectable
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during the procedure. The length of the cecum ligated is a
major determinant of mortality [59]. Moreover, not only does
the distance of cecum ligated influence survival, serum levels
of proinflammatory cytokines such as IL-6 and TNF- are
increased markedly with increasing length of cecum ligated
[59]. Other factors affecting mortality following CLP are size of
needle used for the puncture, the number of punctures, fluid
resuscitation, and antibiotic treatment. As a consequence, it is
of great importance that the procedure of CLP is performed
with high consistency and reproducibility to evaluate findings
obtained from septic animals. In summary, the model of CLP
has become the most widely used model for experimental
sepsis and is currently considered the “gold standard” in
sepsis research, with the caveat that mixed aerobic and anaer-
obic gram-negative bacteria predominate (Table 2).
Nonhuman, primate models of sepsis
Sepsis models involving the i.v. infusion of live E. coli have
been used in baboons. Endpoints have included survival
curves, biochemical evidence of disseminated intravascular
coagulation (DIC), and appearance in serum/plasma of proin-
flammatory cytokines (IL-6, IL-8, TNF-). Treatment with anti-
TNF- or with antithrombin III markedly improved survival,
reduced evidence of DIC, and reduced blood levels of proin-
flammatory cytokines [60–62]. Treatment of E. coli-infused
monkeys with anti-C5a also improved survival and biochemical
parameters of sepsis [63, 64]. Infusion of LPS into baboons or
humans results in appearance of proinflammatory mediators in
blood and evidence of DIC [65, 66]. The infusion of live E. coli
has been described as a type of “acute intoxication” in which
similar blood levels of E. coli are not seen in septic humans
[67]. The levels of TNF- occurring after infusion of LPS or
live E. coli into animals (including mice) are high and sus-
tained, in contrast to the transient levels of TNF- in septic
humans [68]. All of these observations raise the question as to
whether the nonhuman, primate models of sepsis are surrogates
for human sepsis. Because of ethical reasons as well as the lack
of access to intensive care facilities, models of bacterial peri-
tonitis have not generally been used in nonhuman, primates,
creating a gap between rodent models of bacterial peritonitis
and septic humans.
DISCUSSION
In spite of substantial research in experimental sepsis models,
few if any of these promising findings have been shown to be
therapeutically efficacious in septic patients based on clinical
trials [69]. Only three therapeutic strategies that improve pa-
tient outcomes in sepsis are currently being used on intensive
care units. These include administration of low-dose glucocor-
ticoids, intensive insulin therapy, and infusion of activated
protein C (APC) [70–72]. However, APC represents one of the
first approved drug (with restrictions) for the treatment of sepsis
which may affect the inflammatory response. APC specifically
targets the clotting pathway and may affect parameters of the
inflammatory response. Patients with sepsis only benefit from
an early intervention, even if the therapy consists solely of
supportive, nonspecific treatment [73]. Therefore, the question
remains as to whether the animal models currently used to
study sepsis differ too much from septic humans or if research-
ers and physicians get lost in translation when attempting to
adapt their findings into daily practice.
The Shock Society and the International Sepsis Forum ded-
icated a symposium about that issue held on Oak Island, Nova
Scotia, in 2005. There is an abundance of preclinical models of
shock and sepsis, but we have yet to determine if and how
promising findings obtained from these models can be trans-
lated to the setting of human sepsis. Obviously, there are clear
differences between laboratory animals and patients. Mice and
rats are housed in specific pathogen-free areas, may often be
inbred strains, have the same age and weight, and most im-
portantly, do not have comorbidities (such as diabetes, hyper-
tension, and pre-existing immunosuppression among others)
seen in septic humans. In light of the fact that most humans
with sepsis are 50 years old, and as most mice used in sepsis
are 3 months old (with an average lifespan of 24 months), it
is possible that there is a “disconnect” between the study of
mice and humans with sepsis. Furthermore, the experimental
models have a precisely known time period. In contrast, we
encounter patients of different ethnicities, ages, and weight,
and most of the time, we are uncertain when the symptoms first
emerged. In addition, there are differences between rodents
and humans on the molecular level. For instance, human
C-reactive protein (CRP), an acute-phase protein and popular
marker for inflammation, is known to be an activator of the
complement system in humans, but in contrast, rat CRP does
not influence the complement system [74, 75]. The fact that
there are differences between TLRs in mice and in humans
could also affect interpretation of sepsis studies in the two
species [76]. Therefore, the simple transfer of knowledge from
animals to humans is highly illusive. To investigate underlying
pathomechanisms that will allow us to develop effective ther-
apies for sepsis patients, we must aim at models of sepsis that
resemble human sepsis as closely as possible.
Almost all of the sepsis models currently in use involve the
primary administration of bacteria, bacterial cell wall compo-
nents, or other organisms that subsequently trigger the immune
system. However, there are many other initial events such as
burns, major trauma, or surgical procedures that can lead to a
systemic inflammatory response. Therefore, findings obtained
from the CLP model, for example, can be applied to patients
with abdominal perforations as the initial event leading to
peritonitis and sepsis. However, other patients may have ex-
perienced different insults, which may eventually result in
sepsis as well, but other pathways may have been activated,
perhaps explaining why so many clinical trials have failed.
Many immunomodulating strategies have been used on the
basis of experimental data from animal studies. However, the
conditions seen in experimental animal models of sepsis do not
necessarily reflect the pathophysiological situation of patients
with severe sepsis or septic shock. As outlined above, sepsis in
animals and in humans depends on many variables and often
differs in its severity, which in turn may be closely linked to
beneficial effects of immunomodulating strategies. As already
mentioned, except for APC, none of the anti-inflammatory
strategies, which showed promising effects in experimental
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sepsis, has improved the outcome in studies of patients with
sepsis [6]. This may be partly a result of the inhomogeneity of
patient populations in most of the sepsis clinical trials. Here,
inclusion and exclusion criteria seem to be crucial. Although
the above-mentioned definitions for SIRS and sepsis are crit-
icized for being too sensitive and not adequately specific, they
are still commonly used as the standard criteria for the enroll-
ment of patients into clinical trials [77]. This may explain why
some clinical trials involving small numbers of patients showed
significant results, but such beneficial effects failed to materi-
alize in controlled, randomized Phase III trials, as the benefit
of anti-inflammatory therapies in septic animals as well as in
humans with sepsis is tightly linked with the severity of disease
[78]. In other words, the most desperately ill patients had the
greatest benefit. Therefore and as a result of the fact that an
early intervention may be beneficial [73], the establishment of
a reliable system for diagnosing and staging sepsis is required,
just as it is represented by the tumor node metastasis (TNM)
system for classification of malignant tumor diseases. An at-
tempt in this direction was undertaken 2001 with the creation
of the PIRO system as a tool for clinicians as well as for
researchers to diagnose sepsis [10]. Besides the initial injuri-
ous or infective insult and the presence of organ dysfunction,
the patient’s predisposition and current status of the immune
response are taken into account. In the future, a system for
diagnosing and prognosing sepsis should be endorsed by bi-
omarkers such as mediator profiles or receptor status [79].
Based on a “molecular fingerprint” providing information about
the individual situation and stage of disease, patient-targeted,
therapeutic strategies could then be pursued.
With regard to the human sepsis syndrome, sepsis models
such as CLP closely resemble the course of sepsis observed in
patients, characterized by an early hyperdynamic, hypermeta-
bolic state, followed by a pronounced hypodynamic, hypometa-
bolic state. However, we need to realize that there is no single,
ideal model of sepsis. The sepsis syndrome is a complex and a
therapeutically challenging disorder involving several organ
systems. It is in the nature of basic research that usually, single
pathways or mechanisms are being investigated in a rather
isolated manner in experimental models, whereas a septic
patient presents as a complex and interconnected system that
is out of balance. Although one of the attributes of using mice
for basic research lies within the availability of gene knock-
outs, one has to be aware that results obtained from animals
cannot suffice to draw conclusions on an individual patient.
Nevertheless, animal models represent an important and in-
dispensable tool to derive a better understanding of the under-
lying molecular and genetic mechanisms of SIRS and sepsis.
Thereby, the limitations of the particular animal model used to
investigate sepsis must be kept in mind.
WHERE DO WE GO FROM HERE?
How to bridge and extrapolate data from animal sepsis to the
setting of human sepsis is a daunting challenge. As indicated
above, the interventions that have been protective in septic
animals have not shown clinical efficacy in humans. This does
not mean that animal models of sepsis are irrelevant or that
they provide irrelevant information for application to humans.
It is likely that animal models will be useful, provided we
understand their limitations. First, we need to determine what
the most relevant animal models of sepsis are. As suggested
above, the most relevant model is probably not endotoxemia or
massive infusion of live organisms. CLP may be one reasonable
surrogate of human sepsis, but it may not yield information
relevant to the increasing incidence of sepsis caused by gram-
positive bacteria and fungi. Accordingly, it would seem that
several models of sepsis featuring live organisms should be
used. Furthermore, there is nothing wrong with the use of
products from live organisms, such as staphylococcal toxins,
provided limitations in the interpretation of such data are
acknowledged. Second, we need to consider if the use of
nonhuman primates will provide data that are different from
information generated from septic rodents. The major difficulty
here is the expense of such studies, the substantial animal
welfare concerns, and the need to have intensive care-type
facilities if nonhuman primates are to be used. It would cer-
tainly be important to know if the use of the larger animals
resulted in divergent data about the pathophysiology of sepsis
and the mediators involved as compared with findings in ro-
dents. Third, the age of the animals may lead to different data,
as described above. Should animal sepsis studies be rede-
signed to reflect more accurately the corresponding age of
septic humans where advanced age is clearly known to be a
risk factor? Mediator profiles in aging mice might be quite
different from those in young mice and might therefore require
a reassessment of the most important mediators. Fourth, should
animals undergoing sepsis studies be treated in manners sim-
ilar to septic humans? In addition to fluid resuscitation and
broad-spectrum antibiotic treatment, should they receive
agents such as morphine, inotropic drugs, or allogenic blood
transfusions, all of which can lead to immunosuppression as
well as other outcomes?
Clearly, there are no definitive answers, but these observa-
tions underscore the exciting challenges that lie ahead if we are
able to make new progress into more effective, therapeutic
interventions in human sepsis.
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